Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

The concept of time toxicity: A patient's perspective

Dr Christopher Booth - Queen's University, Kingston, Canada
The concept of time toxicity: A patient's perspective ( Dr Christopher Booth - Queen's University, Kingston, Canada )
19 Sep 2022

ESMO 2022: Breast and ovarian trial analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Breast and ovarian trial analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
14 Sep 2022

ESMO 2022: Highlights, commentary and analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Highlights, commentary and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
12 Sep 2022

Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC

Dr Silvia Novello - University of Turin, Turin, Italy
Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC ( Dr Silvia Novello - University of Turin, Turin, Italy )
12 Sep 2022

ESMO 2022: Renal roundup

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
ESMO 2022: Renal roundup ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
12 Sep 2022

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial

Prof Matthew P Goetz - Mayo Clinic, Rochester, USA
Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )
12 Sep 2022

Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-negative breast cancer

Dr Iris Nederlof - The Netherlands Cancer Institute, Amsterdam, Netherlands
Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-negative breast cancer ( Dr Iris Nederlof - The Netherlands Cancer Institute, Amsterdam, Netherlands )
12 Sep 2022

Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum-containing regimen

Prof Siow-Ming Lee - University College London, London, UK
Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum-containing regimen ( Prof Siow-Ming Lee - University College London, London, UK )
12 Sep 2022

Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in pts with NSCLC

Prof Siow-Ming Lee - University College London, London, UK
Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in pts with NSCLC ( Prof Siow-Ming Lee - University College London, London, UK )
12 Sep 2022

RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy to treat prostate cancer

Prof Chris Parker - Institute of Cancer Research, Sutton, UK
RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy to treat prostate cancer ( Prof Chris Parker - Institute of Cancer Research, Sutton, UK )
12 Sep 2022

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer

Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürmann
ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer ( Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürmann )
11 Sep 2022

A new era of early cancer detection with blood test may change cancer screening paradigms

Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA
A new era of early cancer detection with blood test may change cancer screening paradigms ( Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA )
11 Sep 2022